On one hand, scientific innovation is advancing at remarkable speed. Researchers are developing new technologies, exploring new vaccine targets, and expanding vaccination beyond infancy into every stage of life. Vaccine development has been extended to new fields, including cancer, autoimmunity and aging. Moreover, the extended value of vaccination, which is well documented in childhood, is beginning to be seen in adults, such as in the potential effect of certain vaccines on the risk of dementia. On the other hand, funding challenges, growing vaccine hesitancy, and unequal access threaten decades of progress.

In their exploration of the future of vaccination, Dr. Jerome Kim and Prof. Nicaise Ndembi, both of the International Vaccine Institute, describe a world in which vaccines could do far more than protect young children. Their vision is one of life-course vaccination, where protection begins before birth and continues through old age. It is also a vision that depends on overcoming social, political, and economic barriers that are every bit as important as scientific ones.

The story of vaccines is often told through statistics. Since the launch of global immunization efforts in the 1970s, vaccines have saved an estimated 150 million children’s lives. Every year they continue to prevent millions of deaths. Behind those numbers are individual stories of children who grew up healthy, parents who avoided tragedy, and communities that gained the opportunity to thrive.

The success of vaccination has been so profound that many people have never witnessed the diseases vaccines were designed to prevent. Ironically, this success can sometimes make the importance of vaccination less visible. When outbreaks disappear, people may forget how devastating those illnesses once were.

The COVID-19 pandemic reminded the world of both the power and the limitations of vaccines. In record time, scientists developed vaccines that dramatically reduced severe illness and death. Billions of doses were distributed around the globe. At the same time, the pandemic exposed deep inequalities in access. Wealthier nations secured supplies quickly, while many lower-income countries waited far longer for protection.

Those lessons continue to shape discussions about the future of global vaccination. Traditionally, vaccines have focused heavily on infants and young children. This strategy made sense because many dangerous infectious diseases strike early in life. Yet researchers increasingly recognize that important opportunities for protection exist far beyond childhood. School-age children and adolescents represent one of the most important emerging areas for vaccination.

Human papillomavirus, commonly known as HPV, offers a striking example. HPV vaccination can prevent many cases of cervical cancer, one of the most common cancers affecting women worldwide. The science behind these vaccines is strong, and their benefits can last for many years. Despite this, vaccination rates remain far lower than public health experts would like, especially in many low- and middle-income countries.

The challenge is logistical, financial, and social, rather than scientific. Reaching adolescents often requires school-based programs or new healthcare delivery systems. Many countries still struggle to build these programs at the scale needed to protect entire populations.

Another important target is meningococcal disease, a severe infection that can cause meningitis and death. Effective vaccines already exist, yet coverage remains incomplete in many regions. Outbreaks continue to demonstrate the importance of broad protection, particularly in areas where the disease remains common.

Researchers are also pursuing vaccines against diseases that have long been neglected. One example is Group A Streptococcus, the bacterium responsible for strep throat and, in some cases, rheumatic heart disease. This illness continues to cause substantial suffering and death, especially in lower-income countries. Yet vaccine development has progressed slowly because financial incentives are limited.

The burden of disease is high, but the potential commercial market is less attractive than for vaccines aimed at wealthier populations. This challenge highlights an uncomfortable reality. Some of the diseases that cause the greatest suffering receive the least investment because they primarily affect populations with fewer resources.

Another exciting frontier is maternal immunization. Pregnancy presents a unique opportunity to protect two lives at once. When a pregnant woman receives certain vaccines, antibodies can be passed to her baby before birth and through breastfeeding afterward. This early protection can help shield infants during their most vulnerable months.

Influenza vaccination during pregnancy has already demonstrated important benefits for both mothers and newborns. More recently, vaccines against respiratory syncytial virus, or RSV, have opened another promising avenue. RSV is a major cause of severe respiratory illness in infants worldwide. Maternal vaccination can significantly reduce the risk of serious disease during the first months of life.

Scientists are also working on vaccines against Group B Streptococcus, a bacterium that can cause severe infections in newborns and complications during pregnancy. If successful, these vaccines could prevent illness, disability, and death for mothers and babies around the world. Despite these advances, maternal vaccination remains underused in many countries. Better data, stronger healthcare systems, and improved public awareness will be needed to realize its full potential.

Vaccination in older adults represents another major opportunity. As people live longer, protecting health in later life becomes increasingly important. Older adults face elevated risks from influenza, pneumonia, RSV, shingles, and other infectious diseases. Vaccines already exist for many of these threats, yet uptake often remains lower than recommended. The consequences can be serious. Hospitalizations, long-term complications, and deaths from preventable infections continue to affect millions of older people each year.

Emerging research has even raised intriguing questions about whether some vaccines may help reduce the risk of dementia. While scientists are still investigating these findings, the possibility suggests that vaccination could have benefits extending beyond the prevention of infection alone. A future in which vaccination contributes not only to longer life but also to healthier aging would represent a remarkable expansion of its role in medicine.

Scientific innovation is driving many of these possibilities. Among the most widely discussed advances are messenger RNA, or mRNA, vaccines. Although many people first encountered this technology during the COVID-19 pandemic, researchers had been developing it for years. mRNA vaccines offer several advantages. They can be designed quickly, manufactured relatively efficiently, and adapted to new threats. These qualities make them especially valuable during outbreaks and pandemics.

Researchers are now exploring mRNA vaccines for a wide range of infectious diseases. Some targets may prove easier than others. Viruses often present simpler challenges than bacteria, whose biology can be far more complex. Even so, progress continues, and new possibilities emerge every year. The rapid development of COVID-19 vaccines demonstrated what can happen when scientific knowledge, investment, and global urgency align. Future outbreaks may benefit from lessons learned during that experience.

Another area of innovation involves combination vaccines. Many parents are familiar with vaccines that protect against multiple diseases in a single shot. Think: MMR, protecting against measles, mumps, and rubella. Future combination vaccines could simplify immunization schedules even further. Fewer injections could reduce anxiety, improve convenience, and lower healthcare costs.

Researchers are also investigating technologies that release vaccine components gradually over time. Such systems might someday allow multiple doses to be delivered through a single visit, reducing the need for repeat appointments. Meanwhile, microarray patches could transform how vaccines are administered. Instead of traditional needles, these patches use tiny microscopic projections to deliver vaccine through the skin. The potential advantages are significant. Patches may be easier to transport, more stable at ambient temperatures, and less intimidating for people who dislike needles. In remote areas with limited healthcare infrastructure, such technologies could expand access dramatically.

Artificial intelligence is also beginning to influence vaccine development. Modern vaccine design involves analyzing enormous amounts of biological data. Artificial intelligence can help researchers identify promising vaccine targets, predict immune responses, and accelerate parts of the development process. What once required years of analysis may increasingly be accomplished in far less time.

Some experts believe that future vaccine discovery could become substantially faster as artificial intelligence tools continue to improve. Combined with advances in computing and biological science, these technologies may reshape how vaccines are created.

Equally important are innovations in vaccine adjuvants. Adjuvants are ingredients that help strengthen immune responses. For decades, only a limited number of adjuvants were available. Today, scientists have a growing toolkit that can enhance vaccine effectiveness, tailor immune responses, and potentially improve protection for special populations.

These advances illustrate a broader theme. The future of vaccination is being built through many interconnected innovations that improve how vaccines are designed, delivered, and used. Yet scientific progress alone cannot guarantee success.

One of the most important messages emphasized by Dr. Jerome Kim and Prof. Nicaise Ndembi is that implementation matters. A vaccine cannot save lives if people cannot access it. Scientific discovery must be matched by manufacturing capacity, financing, healthcare infrastructure, and public trust.

Funding presents a particularly serious challenge. Global health organizations have faced significant financial pressures in recent years. Reduced funding can slow vaccine development, weaken immunization programs, and limit access in vulnerable communities. At a time when scientific opportunities are expanding, financial constraints threaten to narrow what is possible.

The issue is especially acute for diseases that primarily affect poorer populations. Developing a vaccine is expensive, often requiring years of research and enormous investment. When expected financial returns are limited, companies may hesitate to pursue certain projects, even when public health needs are substantial. Addressing these gaps will require new partnerships, innovative funding mechanisms, and stronger international cooperation.

Equity remains another defining challenge. The COVID-19 pandemic exposed how unevenly vaccine access can be distributed. Many countries are now seeking greater vaccine manufacturing capacity within their own regions. Expanding local and regional production could improve resilience, reduce dependence on distant suppliers, and strengthen health security.

In Africa, Latin America, and other regions, efforts are underway to build manufacturing ecosystems capable of producing vaccines closer to where they are needed. These initiatives represent more than industrial projects. They are investments in scientific capacity, economic development, and health sovereignty.

Finally, there is the challenge of trust. Vaccine hesitancy has emerged as a growing concern in many countries. Misinformation, political polarization, and declining confidence in institutions have all contributed to skepticism about vaccination. Recent outbreaks of measles demonstrate the consequences. Diseases once considered controlled or eliminated have returned in some places because vaccination rates fell below the levels needed for community protection.

Building trust requires listening to concerns, communicating transparently, and maintaining strong relationships between healthcare systems and the communities they serve. The future of vaccination will depend as much – if not more – on human relationships as on scientific discovery.

Looking ahead, the possibilities are extraordinary. Vaccines may protect people at every stage of life, from infancy to old age. New technologies could make vaccines faster to develop, easier to distribute, and more effective than ever before. Diseases that currently have no vaccine solutions may eventually become preventable.

At the same time, progress is not guaranteed. Funding shortfalls, inequities in access, and growing hesitancy could undermine many of these gains. The next chapter in the history of vaccines will be shaped by choices made today. Those choices involve science, certainly, but they also involve values. They involve deciding whether lifesaving innovations should reach everyone, regardless of geography or income. They involve recognizing that vaccines remain one of humanity’s most powerful tools.